A real-world cohort study finds that denosumab use is linked to a lower risk for incident knee osteoarthritis in adults with osteoporosis than the use of bisphosphonates.

Ospomyv and Xbryk, biosimilars to Prolia and Xgeva, received FDA approval for osteoporosis and bone loss treatment. Clinical studies confirmed equivalent efficacy, safety, and pharmacokinetics between ...

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

You can reduce osteoporosis risk with RA and care for bone health through effective treatments, lifestyle changes, and proper screening.

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...